	US 12,332,250 B2
	Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
Christoph H. Ladel, Darmstadt (DE); Hans Guehring, Geisenheim (DE); Anne-Christine Bay-Jensen, Copenhagen (DK); Morten Karsdal, Copenhagen (DK); and Per Qvist, Copenhagen (DK)
Assigned to Merck Patent GmbH, Darmstadt (DE)
Filed by MERCK PATENT GMBH, Darmstadt (DE)
Filed on Sep. 1, 2022, as Appl. No. 17/929,261.
Application 17/929,261 is a continuation of application No. 16/650,878, granted, now 11,467,169, previously published as PCT/EP2018/076391, filed on Sep. 28, 2018.
Claims priority of application No. 17194169 (EP), filed on Sep. 29, 2017; and application No. 18169317 (EP), filed on Apr. 25, 2018.
Prior Publication US 2023/0258659 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); A61K 38/18 (2006.01); A61P 19/04 (2006.01)

CPC G01N 33/6887 (2013.01) [A61K 38/1825 (2013.01); A61P 19/04 (2018.01); G01N 2800/10 (2013.01); G01N 2800/52 (2013.01)]

13 Claims

1. A method for treating a subject having a cartilage disorder characterized by articular cartilage injury or loss of articular cartilage with an FGF-18 compound, comprising the following steps:

a) determining, from a sample, the quantity of at least one biomarker selected from the group consisting of CIM (Collagen type I degraded by metalloproteinase), C3M (Collagen type 3 degraded by metalloproteinase) and CRPM (C-reactive protein degraded by metalloproteinase), and

b) administering intraarticularly the FGF-18 compound in an amount that is about 30-100 μg to the subject having lower than 30.0±2SD ng/mL of CIM (Collagen type I degraded by metalloproteinase) and/or lower than 12.0±2SD ng/mL of C3M (Collagen type 3 degraded by metalloproteinase) and/or lower than 10.0±2SD ng/mL of CRPM (C-reactive protein degraded by metalloproteinase),

wherein the FGF-18 compound comprises amino acid residues 28-196 of SEQ ID NO: 1, optionally fused to a heterologous protein or chemical compound.